Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date

Kristen M Beck, Isabelle M Sanchez, Eric J Yang, Wilson Liao Department of Dermatology, University of California San Francisco, San Francisco, CA, USA Abstract: Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Beck KM, Sanchez IM, Yang EJ, Liao W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	tildrakizumab IL-23 IL-23p19 biologics psoriasis Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/cbdbae5932784b5585b125fc06cef0a8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cbdbae5932784b5585b125fc06cef0a8
record_format	dspace
spelling	oai:doaj.org-article:cbdbae5932784b5585b125fc06cef0a82021-12-02T07:38:55ZProfile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date2230-326Xhttps://doaj.org/article/cbdbae5932784b5585b125fc06cef0a82018-08-01T00:00:00Zhttps://www.dovepress.com/profile-of-tildrakizumab-asmn-in-the-treatment-of-moderate-to-severe-p-peer-reviewed-article-PTThttps://doaj.org/toc/2230-326XKristen M Beck, Isabelle M Sanchez, Eric J Yang, Wilson Liao Department of Dermatology, University of California San Francisco, San Francisco, CA, USA Abstract: Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years in understanding the immune-mediated pathophysiology of psoriasis have led to the development of targeted biologic therapies for this condition. Currently, biologic medications approved for the treatment of plaque psoriasis include tumor necrosis factor α inhibitors, interleukin (IL)-17 or IL-17 receptor inhibitors, IL-12/23 inhibitors, and IL-23 inhibitors. Tildrakizumab-asmn is a monoclonal antibody that targets the p19 subunit of IL-23 and is approved for use in adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. This article reviews the current pharmacologic, efficacy, and safety data on tildrakizumab-asmn. Keywords: tildrakizumab, IL-23, IL-23p19, biologics, psoriasisBeck KMSanchez IMYang EJLiao WDove Medical PressarticletildrakizumabIL-23IL-23p19biologicspsoriasisDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol Volume 8, Pp 49-58 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	tildrakizumab IL-23 IL-23p19 biologics psoriasis Dermatology RL1-803
spellingShingle	tildrakizumab IL-23 IL-23p19 biologics psoriasis Dermatology RL1-803 Beck KM Sanchez IM Yang EJ Liao W Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
description	Kristen M Beck, Isabelle M Sanchez, Eric J Yang, Wilson Liao Department of Dermatology, University of California San Francisco, San Francisco, CA, USA Abstract: Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years in understanding the immune-mediated pathophysiology of psoriasis have led to the development of targeted biologic therapies for this condition. Currently, biologic medications approved for the treatment of plaque psoriasis include tumor necrosis factor α inhibitors, interleukin (IL)-17 or IL-17 receptor inhibitors, IL-12/23 inhibitors, and IL-23 inhibitors. Tildrakizumab-asmn is a monoclonal antibody that targets the p19 subunit of IL-23 and is approved for use in adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. This article reviews the current pharmacologic, efficacy, and safety data on tildrakizumab-asmn. Keywords: tildrakizumab, IL-23, IL-23p19, biologics, psoriasis
format	article
author	Beck KM Sanchez IM Yang EJ Liao W
author_facet	Beck KM Sanchez IM Yang EJ Liao W
author_sort	Beck KM
title	Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
title_short	Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
title_full	Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
title_fullStr	Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
title_full_unstemmed	Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
title_sort	profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/cbdbae5932784b5585b125fc06cef0a8
work_keys_str_mv	AT beckkm profileoftildrakizumabasmninthetreatmentofmoderatetosevereplaquepsoriasisevidencetodate AT sanchezim profileoftildrakizumabasmninthetreatmentofmoderatetosevereplaquepsoriasisevidencetodate AT yangej profileoftildrakizumabasmninthetreatmentofmoderatetosevereplaquepsoriasisevidencetodate AT liaow profileoftildrakizumabasmninthetreatmentofmoderatetosevereplaquepsoriasisevidencetodate
_version_	1718399305113403392

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date

Ejemplares similares